Skip to content

PTHS PTHS Impairment of intangible assets

Impairment of intangible assets at other companies

Grid Dynamics Holdings, Inc. logo
Grid Dynamics Holdings, Inc.GDYN
$0
American Healthcare REIT logo
American Healthcare REITAHR
$0
Accel Entertainment logo
Accel EntertainmentACEL
$0-100%
RDI
Reading International, Inc.RDI
$0
Brand Engagement Network, Inc. logo
Brand Engagement Network, Inc.BNAI
$3.37M
CarGurus, Inc. logo
CarGurus, Inc.CARG
$1.65M-13.2%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsFinitelived.

The official record: PTHS’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's impairment of intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's impairment of intangible assets?
PTHS (PTHS) reported impairment of intangible assets of $71.25K in Q4 2025.
What does impairment of intangible assets mean?
This represents a non-cash charge recognized when the carrying amount of an intangible asset exceeds its fair value, indicating a decline in the asset's expected future economic benefit. For a biotechnology firm, this often reflects adjustments to the valuation of intellectual property or clinical trial assets. It serves as a key indicator of potential risks regarding the long-term viability of the company's research portfolio.